Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Open accessAbstract
Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months ...
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 2 cited sources checked · 0 supported · 0 flagged
- Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Using a power-law model, the estimated half-life of binding antibodies after day 43 across all participants was 109 days (95% CI, 92 to 136) at day 119.
“and 109 days (95% CI, 92 to 136) calculated with the use of a power-law model (at day 119)”
Quote in the paperSubstantial claim- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
- Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
For live-virus neutralization, the estimated neutralizing antibody half-life was 182 days (95% CI, 153 to 254) under the power-law model.
“and 66 days (95% CI, 59 to 72) and 182 days (95% CI, 153 to 254) for live-virus neutralization.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
- Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Using an exponential decay model, the estimated half-life of binding antibodies after day 43 across all participants was 52 days (95% CI, 46 to 58).
“The estimated half-life of binding antibodies after day 43 for all the participants was 52 days (95% CI, 46 to 58) calculated with the use of an exponential decay model”
Quote in the paperSubstantial claim- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
- Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
For pseudovirus neutralization, the estimated neutralizing antibody half-life was 69 days (95% CI, 61 to 76) under the exponential model.
“The neutralizing antibody half-life estimates in the two models were 69 days (95% CI, 61 to 76) and 173 days (95% CI, 144 to 225) for pseudovirus neutralization”
Quote in the paperSubstantial claim- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
- Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
In participants aged 18 to 55, the pseudovirus neutralization ID50 GMT at day 209 was 80 (95% CI, 40 to 135).
“with 50% inhibitory dilution (ID50) GMTs of 80 (95% CI, 40 to 135), 57 (95% CI, 30 to 106), and 59 (95% CI, 29 to 121), respectively.”
Quote in the paperSubstantial claim
- Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
In participants aged 71 or older, the binding antibody GMT at day 209 was 49,373 (95% CI, 25,171 to 96,849).
“49,373 (95% CI, 25,171 to 96,849) in those 71 years of age or older.”
Quote in the paperSubstantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
According to ΔAICc, the exponential decay model provided the best fit for neutralization.
“As measured by ΔAICc (change in Akaike information criterion, corrected for small sample size), the best fit for binding and neutralization were the power-law and exponential decay models, respectively”
Quote in the paperSubstantial claim- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
- Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
In participants aged 56 to 70, the binding antibody GMT at day 209 was 62,424 (95% CI, 36,765 to 105,990).
“62,424 (95% CI, 36,765 to 105,990) in those 56 to 70 years of age”
Quote in the paperSubstantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
For pseudovirus neutralization, the estimated neutralizing antibody half-life was 173 days (95% CI, 144 to 225) under the power-law model.
“The neutralizing antibody half-life estimates in the two models were 69 days (95% CI, 61 to 76) and 173 days (95% CI, 144 to 225) for pseudovirus neutralization”
Quote in the paperSubstantial claim- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
- Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
The live-virus neutralization GMT was lower in the 56-to-70 age group than in the 18-to-55 group, with P=0.03.
“these GMTs were lower in participants 56 to 70 years of age (P=0.03) and in those 71 years of age or older (P=0.005) than in those 18 to 55 years of age”
Quote in the paperNot a substantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Antibodies induced by mRNA-1273 remained detectable 6 months after the second dose, as shown by three different serologic assays.
“Although the antibody titers and assays that best correlate with vaccine efficacy are not currently known, antibodies that were elicited by mRNA-1273 persisted through 6 months after the second dose, as detected by three distinct serologic assays.”
- Also stated in: § Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 · plain
“Our data show antibody persistence and thus support the use of this vaccine in addressing the Covid-19 pandemic.”
Quote in the paperSubstantial claim - Also stated in: § Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 · plain
- Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
In participants aged 18 to 55, the live-virus neutralization ID50 GMT at day 209 was 361 (95% CI, 258 to 504).
“with ID50 GMTs of 361 (95% CI, 258 to 504), 171 (95% CI, 95 to 307), and 131 (95% CI, 69 to 251), respectively”
Quote in the paperSubstantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
All participants had detectable live-virus neutralization activity on the mNeonGreen focus-reduction test at day 209.
“On the more sensitive live-virus focus-reduction neutralization mNeonGreen test,4 all the participants had detectable activity, with ID50 GMTs of 361 (95% CI, 258 to 504), 171 (95% CI, 95 to 307), and 131 (95% CI, 69 to 251), respectively”
Quote in the paperSubstantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
In participants aged 56 to 70, the pseudovirus neutralization ID50 GMT at day 209 was 57 (95% CI, 30 to 106).
“with 50% inhibitory dilution (ID50) GMTs of 80 (95% CI, 40 to 135), 57 (95% CI, 30 to 106), and 59 (95% CI, 29 to 121), respectively.”
Quote in the paperSubstantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
In participants aged 71 or older, the pseudovirus neutralization ID50 GMT at day 209 was 59 (95% CI, 29 to 121).
“with 50% inhibitory dilution (ID50) GMTs of 80 (95% CI, 40 to 135), 57 (95% CI, 30 to 106), and 59 (95% CI, 29 to 121), respectively.”
Quote in the paperSubstantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
In participants aged 71 or older, the live-virus neutralization ID50 GMT at day 209 was 131 (95% CI, 69 to 251).
“with ID50 GMTs of 361 (95% CI, 258 to 504), 171 (95% CI, 95 to 307), and 131 (95% CI, 69 to 251), respectively”
Quote in the paperSubstantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Antibody activity was high in every age group at day 209 following the second dose.
“Antibody activity remained high in all age groups at day 209.”
Quote in the paperSubstantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
The live-virus neutralization GMT was lower in the 71-or-older age group than in the 18-to-55 group, with P=0.005.
“these GMTs were lower in participants 56 to 70 years of age (P=0.03) and in those 71 years of age or older (P=0.005) than in those 18 to 55 years of age”
Quote in the paperNot a substantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
For live-virus neutralization, the estimated neutralizing antibody half-life was 66 days (95% CI, 59 to 72) under the exponential model.
“and 66 days (95% CI, 59 to 72) and 182 days (95% CI, 153 to 254) for live-virus neutralization.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
- Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
In participants aged 56 to 70, the live-virus neutralization ID50 GMT at day 209 was 171 (95% CI, 95 to 307).
“with ID50 GMTs of 361 (95% CI, 258 to 504), 171 (95% CI, 95 to 307), and 131 (95% CI, 69 to 251), respectively”
Quote in the paperSubstantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Almost all participants showed detectable pseudovirus neutralization activity at day 209.
“Nearly all participants had detectable activity in a pseudovirus neutralization assay,2 with 50% inhibitory dilution (ID50) GMTs of 80 (95% CI, 40 to 135), 57 (95% CI, 30 to 106), and 59 (95% CI, 29 to 121), respectively.”
Quote in the paperSubstantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
In participants aged 18 to 55, the geometric mean end-point titer of binding antibodies against the SARS-CoV-2 spike receptor-binding domain at day 209 was 92,451 (95% CI, 57,148 to 149,562).
“Binding antibodies, measured by means of an enzyme-linked immunosorbent assay against SARS-CoV-2 spike receptor–binding domain,2 had geometric mean end-point titers (GMTs) of 92,451 (95% confidence interval [CI], 57,148 to 149,562) in participants 18 to 55 years of age”
Quote in the paperSubstantial claim - Findingown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
According to ΔAICc, the power-law model provided the best fit for binding antibodies.
“As measured by ΔAICc (change in Akaike information criterion, corrected for small sample size), the best fit for binding and neutralization were the power-law and exponential decay models, respectively”
Quote in the paperSubstantial claim- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
- Interpretationown data§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
The data support using the mRNA-1273 vaccine to address the Covid-19 pandemic.
“Our data show antibody persistence and thus support the use of this vaccine in addressing the Covid-19 pandemic.”
Quote in the paperNot a substantial claim
- Classified as probably not a substantial claim. 2
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19A phase 3 trial of the Moderna mRNA-1273 vaccine reported 94% efficacy against Covid-19 in interim findings.
“Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).1”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [1] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403- 416. 33378609 PMC7787219 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Interpretationcitation§ Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19The present findings align with previously published observations of convalescent Covid-19 patients followed for up to 8 months after symptom onset.
“These results are consistent with published observations of convalescent patients with Covid-19 through 8 months after symptom onset.5”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [5] Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371(6529): eabf4063- eabf4063. 33408181 PMC7919858 source
Not checked in the free run.
The paper relies on this without support.
The durability of protection from the mRNA-1273 vaccine is currently unknown.
“The durability of protection is currently unknown.”
The authors state this as an assumption.
The exponential decay model assumes a constant antibody decay rate over time.
“which assumes a steady decay rate over time”
The authors state this as an assumption.
The power-law model assumes that antibody decay rates decrease over time.
“which assumes that decay rates decrease over time”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Circulating antibodies persist for at least 6 months postvaccination, although there is some decay from peak levels.
“Current evidence suggests that circulating antibodies persist for at least 6 months postvaccination (7), although there is some decay from the peak levels achieved after the second dose.”
From mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern (2021) · cites this paper as [7]
Vaccination with mRNA-1273 elicited antibodies to SARS-CoV-2 WA1 in subjects aged 56 to 70 and 71 and older that are as potent and durable as those elicited in adults aged 18 to 55, with a slight decrease in potency for the oldest subjects in live-virus neutralization.
“We previously showed that vaccination with mRNA-1273 elicited antibodies to SARS-CoV-2 WA1 in subjects aged 56 to 70 and 71 and older that are as potent (15) and durable (13) as those elicited in adults aged 18 to 55, with a slight decrease in potency for the oldest subjects in live-virus neutralization (13).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [13]
In the pseudovirus neutralization assay, 25% of sera neutralized WA1 after one dose (day 29).
“In the pseudovirus neutralization assay, consistent with our previous study (13), 25% of sera neutralized WA1 after one dose (day 29).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [13]
In clinical trials, two doses of mRNA-1273 elicited durable antibody responses over a period of 6 months; although antibody titres declined slightly, high neutralizing ability was retained across all age groups.
“In clinical trials, two doses of mRNA-1273 also elicited durable antibody responses over a period of 6 months. Although antibody titres declined slightly over the duration of the study, high neutralizing ability was retained across all age groups205.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [205]
Neutralizing antibody responses raised by mRNA COVID-19 vaccines decay with a half-life of 69-173 days.
“Several reports have measured the decay of neutralizing antibody responses raised by mRNA COVID-19 vaccines with a half-life of 69-173 days (Doria-Rose et al., 2021; Levin et al., 2021).”
From mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2022) · cites this paper as Doria-Rose et al., 2021
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works
Self-citationImmunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · see citing works
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523 · see citing works
Self-citationDurability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2032195 · Cited by 722 · see citing works
Self-citation
Flagged first, then by citations
1 of the 6 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.033 · Cited by 1,045 · see citing works
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911 · see citing works
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · Science · doi:10.1126/science.abm0829 · Cited by 873 · see citing works
Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jürjenson, V., Adamson, A., Haljasmägi, L., Rumm, A. P., Maruste, R., Kärner, J., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100208 · Cited by 629 · see citing works
T cell responses to SARS-CoV-2 spike cross-recognize Omicron
Keeton, R., Tincho, M. B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S., Bernstein, M. P., Karim, F., et al. (2022) · Nature · doi:10.1038/s41586-022-04460-3 · Cited by 610 · see citing works
Humoral and cellular immune memory to four COVID-19 vaccines
Zhang, Z., Mateus, J., Coelho, C. H., Dan, J. M., Moderbacher, C. R., Gálvez, R. I., Côrtes, F. H., Grifoni, A., Tarke, A., Chang, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.022 · Cited by 567 · see citing works
Systems vaccinology of the BNT162b2 mRNA vaccine in humans
Arunachalam, P. S., Scott, M. K. D., Hagan, T., Li, C., Feng, Y., Wimmers, F., Grigoryan, L., Trisal, M., Edara, V. V., Lai, L., et al. (2021) · Nature · doi:10.1038/s41586-021-03791-x · Cited by 541 · see citing works
Self-citationDurability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527 · see citing works
Self-citationEfficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Lee, A. R. Y. B., Wong, S. Y., Chai, L. Y. A., Lee, S. C., Lee, M. X., Muthiah, M. D., Tay, S. H., Teo, C. B., Tan, B. K. J., Chan, Y. H., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068632 · Cited by 493 · see citing works
Cohen, K. W., Linderman, S. L., Moodie, Z., Czartoski, J., Lai, L., Mantus, G., Norwood, C., Nyhoff, L. E., Edara, V. V., Floyd, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100354 · Cited by 441 · see citing works
Self-citationCovid-19 Vaccines — Immunity, Variants, Boosters
Barouch, D. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2206573 · Cited by 434 · see citing works
Choi, A., Koch, M., Wu, K., Chu, L., Ma, L., Hill, A., Nunna, N., Huang, W., Oestreicher, J., Colpitts, T., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01527-y · Cited by 396 · see citing works
Self-citationEvaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents
Ali, K., Berman, G., Zhou, H., Deng, W., Faughnan, V., Coronado-Voges, M., Ding, B., Dooley, J., Girard, B., Hillebrand, W., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109522 · Cited by 377 · see citing works
Self-citationZeng, G., Wu, Q., Pan, H., Li, M., Yang, J., Wang, L., Wu, Z., Jiang, D., Deng, X., Chu, K., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00681-2 · Cited by 317 · see citing works
SARS-CoV-2 Variants, Vaccines, and Host Immunity
Mistry, P., Barmania, F., Mellet, J., Peta, K. T., Strydom, A., Viljoen, I. M., James, W., Gordon, S., & Pepper, M. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.809244 · Cited by 293 · see citing works
Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282 · see citing works
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Sette, A., & Crotty, S. (2022) · Immunological Reviews · doi:10.1111/imr.13089 · Cited by 266 · see citing works
mRNA Vaccines in the COVID-19 Pandemic and Beyond
Hogan, M. J., & Pardi, N. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-112725 · Cited by 252 · see citing works
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
Barouch, D. H., Stephenson, K. E., Sadoff, J., Yu, J., Chang, A., Gebre, M., McMahan, K., Liu, J., Chandrashekar, A., Patel, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2108829 · Cited by 237 · see citing works
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y., & Wallace, A. W. (2021) · Science · doi:10.1126/science.abm0620 · Cited by 230 · see citing works
Review of COVID-19 vaccine subtypes, efficacy and geographical distributions
Francis, A. I., Ghany, S., Gilkes, T., & Umakanthan, S. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2021-140654 · Cited by 216 · see citing works
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
Grainger, R., Kim, A. H. J., Conway, R. P., Yazdany, J., & Robinson, P. C. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00755-x · Cited by 185 · see citing works
Immunity to SARS‐CoV‐2 induced by infection or vaccination
Dopico, X. C., Ols, S., Loré, K., & Hedestam, G. B. K. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 164 · see citing works
Antibody titres decline 3-month post-vaccination with BNT162b2
Favresse, J., Bayart, J., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S. V., Roy, T., Wieërs, G., Laurent, C., Dogné, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1953403 · Cited by 151 · see citing works
Oosting, S. F., van der Veldt, A. A. M., GeurtsvanKessel, C. H., Fehrmann, R. S. N., van Binnendijk, R. S., Dingemans, A. C., Smit, E. F., Hiltermann, T. J. N., den Hartog, G., Jalving, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00574-x · Cited by 150 · see citing works
Antibody-mediated neutralization of SARS-CoV-2
Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 145 · see citing works
Extended interval BNT162b2 vaccination enhances peak antibody generation
Parry, H., Bruton, R. K., Stephens, C., Bentley, C., Brown, K. E., Amirthalingam, G., Hallis, B., Otter, A. D., Zuo, J., & Moss, P. A. H. (2022) · npj Vaccines · doi:10.1038/s41541-022-00432-w · Cited by 144 · see citing works
Notarte, K. I., Guerrero‐Arguero, I., Velasco, J. V., Ver, A. T., de Oliveira, M. H. S., Catahay, J. A., Khan, M. S. R., Pastrana, A. M., Juszczyk, G., Torrelles, J. B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27688 · Cited by 143 · see citing works
Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy
Jiang, Y.-Z., Rubin, L., Peng, T., Liu, L., Xing, X., Lazarovici, P., & Zheng, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59272 · Cited by 141 · see citing works
COVID-19 in patients with hematologic malignancy
Langerbeins, P., & Hallek, M. J. (2022) · Blood · doi:10.1182/blood.2021012251 · Cited by 141 · see citing works
Čiučiulkaitė, I., Möhlendick, B., Thümmler, L., Fisenkci, N., Elsner, C., Dittmer, U., Siffert, W., & Lindemann, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.932043 · Cited by 132 · see citing works
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
Hassan, A. O., Shrihari, S., Gorman, M. J., Ying, B., Yuan, D., Raju, S., Chen, R. E., Dmitriev, I. P., Kashentseva, E. A., Adams, L. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109452 · Cited by 129 · see citing works
Self-citationWong, L. P., Alias, H., Danaee, M., Ahmed, J., Lachyan, A. S., Cai, C. Z., Lin, Y., Hu, Z., Tan, S. Y., Lu, Y., et al. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00900-w · Cited by 128 · see citing works
Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
Liu, Y., Zeng, Q., Deng, C., Li, M., Li, L., Liu, D., Liu, M., Ruan, X., Mei, J., Mo, R., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00373-7 · Cited by 122 · see citing works
Lew, T. T. S., Aung, K. M. M., Ow, S. Y., Amrun, S. N., Sutarlie, L., Ng, L. F. P., & Su, X. (2021) · ACS Nano · doi:10.1021/acsnano.1c04091 · Cited by 114 · see citing works
Chen, X., Chen, Z., Azman, A. S., Sun, R., Lu, W., Zheng, N., Zhou, J., Wu, Q., Deng, X., Zhao, Z., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab646 · Cited by 113 · see citing works
Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
Bates, T. A., Leier, H. C., Lyski, Z. L., McBride, S. K., Coulter, F. J., Weinstein, J. B., Goodman, J. R., Lu, Z., Siegel, S. A. R., Sullivan, P. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25479-6 · Cited by 113 · see citing works
Antibody titers and protection against a SARS-CoV-2 infection
Dimeglio, C., Hérin, F., Martin‐Blondel, G., Miédougé, M., & Izopet, J. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.09.013 · Cited by 113 · see citing works
Liu, Z., Zhou, J., Xu, W., Deng, W., Wang, Y., Wang, M., Wang, Q., Hsieh, M. K., Dong, J., Wang, X., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00612-2 · Cited by 108 · see citing works
Tan, A. T., Lim, J. M. E., Bert, N. L., Kunasegaran, K., Chia, A., Qui, M., Tan, N., Chia, W. N., de Alwis, R., Ying, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152379 · Cited by 106 · see citing works
COVID-19 vaccine – Long term immune decline and breakthrough infections
Khoury, J., Najjar‐Debbiny, R., Hanna, A., Jabbour, A. R., Ahmad, Y. A., Saffuri, A., Abu-Sinni, M., Shkeiri, R., Elemy, A., & Hakim, F. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.038 · Cited by 104 · see citing works
Tauzin, A., Gong, S. Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.004 · Cited by 103 · see citing works
Durability of immune responses to mRNA booster vaccination against COVID-19
Arunachalam, P. S., Lai, L., Samaha, H., Feng, Y., Hu, M., Hui, H. S.-Y., Wali, B., Ellis, M. L., Davis-Gardner, M. E., Huerta, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167955 · Cited by 100 · see citing works
Self-citationPrevious COVID-19 Infection and Antibody Levels After Vaccination
Ali, H., Alahmad, B., Al‐Shammari, A. A., Alterki, A., Hammad, M. M., Cherian, P., Al‐Khairi, I., Sindhu, S. T. A. K., Thanaraj, T. A., Mohammad, A., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.778243 · Cited by 99 · see citing works
Pascarella, S., Ciccozzi, M., Zella, D., Bianchi, M., Benedetti, F., Benvenuto, D., Broccolo, F., Cauda, R., Caruso, A., Angeletti, S., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27210 · Cited by 98 · see citing works
Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates
Corbett, K. S., Gagné, M., Wagner, D. A., Connell, S. O., Narpala, S., Flebbe, D. R., Andrew, S. F., Davis, R. L., Flynn, B. J., Johnston, T. S., et al. (2021) · Science · doi:10.1126/science.abl8912 · Cited by 95 · see citing works
Self-citationCurrent and future nanoparticle vaccines for COVID-19
Vu, M. N., Kelly, H. G., Kent, S. J., & Wheatley, A. K. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103699 · Cited by 95 · see citing works
Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans
Haveri, A., Ekström, N., Solastie, A., Virta, C., Österlund, P., Isosaari, E., Nohynek, H., PALMU, A. A. I., & Melin, M. M. (2021) · European Journal of Immunology · doi:10.1002/eji.202149535 · Cited by 85 · see citing works
Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster
Wu, K., Choi, A., Koch, M., Ma, L., Hill, A., Nunna, N., Huang, W., Oestreicher, J., Colpitts, T., Bennett, H., et al. (2021) · doi:10.1101/2021.05.05.21256716 · Cited by 84 · see citing works
Self-citationMarjot, T., Eberhardt, C. S., Boettler, T., Belli, L. S., Berenguer, M., Buti, M., Jalan, R., Mondelli, M. U., Moreau, R., Shouval, D., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.008 · Cited by 84 · see citing works
Tretyn, A., Szczepanek, J., Skorupa, M., Jarkiewicz‐Tretyn, J., Sandomierz, D., Dejewska, J., Ciechanowska, K., Jarkiewicz-Tretyn, A., Koper, W., & Pałgan, K. (2021) · Cells · doi:10.3390/cells10081952 · Cited by 82 · see citing works
Wang, C. Y., Hwang, K.-P., Kuo, H.-K., Peng, W.-J., Shen, Y.-H., Kuo, B.-S., Huang, J.-H., Liu, H., Ho, Y.-H., Lin, F., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157707 · Cited by 78 · see citing works
Biological Nanoparticles in Vaccine Development
Curley, S. M., & Putnam, D. A. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.867119 · Cited by 76 · see citing works
Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
Muruato, A. E., Vu, M. N., Johnson, B. A., Davis-Gardner, M. E., Vanderheiden, A., Lokugamage, K. G., Schindewolf, C., Crocquet-Valdes, P. A., Langsjoen, R. M., Plante, J. A., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001284 · Cited by 75 · see citing works
Self-citationNiessl, J., Sekine, T., & Buggert, M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101505 · Cited by 74 · see citing works
Thuluva, S., Paradkar, V. M., Gunneri, S., Yerroju, V., Mogulla, R. R., Turaga, K., Kyasani, M., Manoharan, S. K., Medigeshi, G. R., Singh, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104217 · Cited by 74 · see citing works
Lim, J. M. E., Hang, S. K., Hariharaputran, S., Chia, A., Tan, N., Lee, E. S., Chng, E., Lim, P. L., Young, B. E., Lye, D. C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100793 · Cited by 73 · see citing works
Moncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmerón, G., Molina, M. J., Vidal, M., Barrios, D., Mitchell, R. A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103805 · Cited by 73 · see citing works
Gagné, M., Corbett, K. S., Flynn, B. J., Foulds, K. E., Wagner, D. A., Andrew, S. F., Todd, J.-P. M., Honeycutt, C. C., McCormick, L., Nurmukhambetova, S. T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.12.002 · Cited by 71 · see citing works
Self-citationMaeda, K., Amano, M., Uemura, Y., Tsuchiya, K., Matsushima, T., Noda, K., Shimizu, Y., Fujiwara, A., Takamatsu, Y., Ichikawa, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01930-y · Cited by 71 · see citing works
Bajema, K. L., Dahl, R. M., Evener, S. L., Prill, M. M., Rodriguez‐Barradas, M. C., Marconi, V. C., Beenhouwer, D. O., Holodniy, M., Lucero-Obusan, C. A., Brown, S. T., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7049a2 · Cited by 71 · see citing works
Lau, E. H. Y., Hui, D. S. C., Tsang, O. T., Chan, W. H., Kwan, M. Y. W., Chiu, S. S. S., Cheng, S. M. S., Ko, R. L., Li, J. K., Chaothai, S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101174 · Cited by 70 · see citing works
Brufau, S. R., Chopra, A., Ryu, A. J., Gel, E. S., Raskar, R., Kremers, W. K., Anderson, K. S., Subramanian, J., Krishnamurthy, B., Singh, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1087 · Cited by 69 · see citing works
Tré‐Hardy, M., Cupaiolo, R., Wilmet, A., Antoine-Moussiaux, T., Vecchia, A. D., Horeanga, A., Papleux, E., Vekemans, M., Beukinga, I., & Blairon, L. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.08.031 · Cited by 69 · see citing works
COVID ‐19: vaccination problems
Brüssow, H. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15549 · Cited by 66 · see citing works
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Ludwig, H., Sonneveld, P., Facon, T. T. F., Miguel, J. F. S., Avet‐Loiseau, H., Mohty, M., Mateos, M.-V., Moreau, P., Cavo, M., Pawlyn, C., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00278-7 · Cited by 65 · see citing works
Defending against SARS-CoV-2: The T cell perspective
Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 64 · see citing works
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortés, J., Romero, P. J., Mittendorf, E., Disis, M. L., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2153 · Cited by 63 · see citing works
Durability of immune responses to the BNT162b2 mRNA vaccine
Suthar, M. S., Arunachalam, P. S., Hu, M., Reis, N., Trisal, M., Raeber, O., Chinthrajah, R. S., Davis-Gardner, M. E., Manning, K. E., Mudvari, P., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.005 · Cited by 60 · see citing works
Self-citationSix-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors
Waldhorn, I., Holland, R., Goshen‐Lago, T., Shirman, Y., Szwarcwort‐Cohen, M., Benaim, A. R., Shachor‐Meyouhas, Y., Hussein, K., Fahoum, L., Peer, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1072 · Cited by 59 · see citing works
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months
Hsu, C. M., Weiner, D. E., Manley, H. J., Aweh, G. N., Ladik, V., Frament, J., Miskulin, D., Agyropoulos, C., Abreo, K. D., Chin, A., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12250921 · Cited by 59 · see citing works
Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · Nature · doi:10.1038/s41586-024-08511-9 · Cited by 59 · see citing works
Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa
Reddy, K. P., Fitzmaurice, K. P., Scott, J. A., Harling, G., Lessells, R. J., Panella, C., Shebl, F. M., Freedberg, K. A., & Siedner, M. J. (2021) · Nature Communications · doi:10.1038/s41467-021-26557-5 · Cited by 58 · see citing works
Americo, J. L., Cotter, C. A., Earl, P. L., Liu, R., & Moss, B. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2202069119 · Cited by 57 · see citing works
COVID-19 Vaccination in Pregnancy and Lactation: Current Research and Gaps in Understanding
Shook, L. L., Fallah, P. N., Silberman, J. N., & Edlow, A. G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.735394 · Cited by 56 · see citing works
Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
Tan, C. S., Collier, A.-R. Y., Yu, J., Liu, J., Chandrashekar, A., McMahan, K., Jacob-Dolan, C., He, X., Roy, V., Hauser, B. M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.26335 · Cited by 56 · see citing works
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
Jeewandara, C., Aberathna, I. S., Pushpakumara, P. D., Kamaladasa, A., Guruge, D., Wijesinghe, A., Gunasekera, B., Ramu, S. T., Kuruppu, H., Ranasinghe, T., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.621 · Cited by 54 · see citing works
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang, Z., Peng, L., Filler, R. B., Suzuki, K., McNamara, A., Lin, Q., Renauer, P. A., Yang, L., Menasché, B. L., Sanchez, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30878-4 · Cited by 54 · see citing works
Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 53 · see citing works
The way of SARS-CoV-2 vaccine development: success and challenges
Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 53 · see citing works
Delivery Routes for COVID-19 Vaccines
Park, J. H., & Lee, H. K. (2021) · Vaccines · doi:10.3390/vaccines9050524 · Cited by 53 · see citing works
Pang, A. P. S., Higgins‐Chen, A., Comite, F., Raica, I., Arboleda, C., Went, H., Mendez, T. L., Schotsaert, M., Dwaraka, V. B., Smith, R. C., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.819749 · Cited by 52 · see citing works
Nanomechanical action opens endo-lysosomal compartments
Zhao, Y., Ye, Z., Song, D., Wich, D., Gao, S., Khirallah, J., & Xu, Q. (2023) · Nature Communications · doi:10.1038/s41467-023-42280-9 · Cited by 52 · see citing works
Sanders, J., Messchendorp, A. L., de Vries, R. D., Baan, C. C., van Baarle, D., van Binnendijk, R. S., Diavatopoulos, D. A., Geers, D., Schmitz, K. S., GeurtsvanKessel, C. H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac557 · Cited by 51 · see citing works
Arunachalam, P. S., Feng, Y., Ashraf, U., Hu, M., Walls, A. C., Edara, V. V., Zarnitsyna, V. I., Aye, P. P., Golden, N., Miranda, M. C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4130 · Cited by 51 · see citing works
Self-citationLozano‐Rodríguez, R., Valentín‐Quiroga, J., Ortiz, J. A., Martín‐Quirós, A., Pascual‐Iglesias, A., Terrón‐Arcos, V., Montalbán-Hernández, K. M., Casalvilla‐Dueñas, J. C., Bergón-Gutiérrez, M., Alcamı́, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110235 · Cited by 50 · see citing works
Routhu, N. K., Gangadhara, S., Lai, L., Davis-Gardner, M. E., Floyd, K. A., Shiferaw, A., Bartsch, Y. C., Fischinger, S., Khoury, G., Rahman, S. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo0226 · Cited by 50 · see citing works
Self-citationAre COVID-19 Vaccine Boosters Needed? The Science behind Boosters
Burckhardt, R. M., Dennehy, J. J., Poon, L. L. M., Saif, L. J., & Enquist, L. W. (2021) · Journal of Virology · doi:10.1128/jvi.01973-21 · Cited by 50 · see citing works
Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2
Lake, D. F., Roeder, A. J., Kaleta, E. J., Jasbi, P., Pfeffer, K., Koelbela, C., Periasamy, S., Kuzmina, N. A., Bukreyev, A. A., Grys, T. E., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.105024 · Cited by 49 · see citing works
Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization
Cheng, Z. J., Huang, H., Zheng, P., Xue, M., Ma, J., Zhan, Z., Gan, H., Zeng, Y., Lin, R., Li, S., et al. (2022) · Allergy · doi:10.1111/all.15271 · Cited by 49 · see citing works
Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
Ao, L., Lu, T., Cao, Y., Chen, Z., Wang, Y., Li, Z., Ren, X., Xu, P., Peng, M., Chen, M., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2059401 · Cited by 49 · see citing works
Shimizu, J., Sasaki, T., Koketsu, R., Morita, R., Yoshimura, Y., Murakami, A., Saito, Y., Kusunoki, T., Samune, Y., Nakayama, E. E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19993-w · Cited by 48 · see citing works
Valanparambil, R. M., Carlisle, J. W., Linderman, S. L., Akhtar, A., Millett, R. L., Lai, L., Chang, A., McCook‐Veal, A. A., Switchenko, J. M., Nasti, T. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02986 · Cited by 48 · see citing works
Self-citationDurability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
Eliakim‐Raz, N., Massarweh, A., Stemmer, A., & Stemmer, S. M. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4390 · Cited by 47 · see citing works
Brisotto, G., Muraro, E., Montico, M., Corso, C., Evangelista, C., Casarotto, M., Caffau, C., Vettori, R., Cozzi, M. R., Zanussi, S., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.10.035 · Cited by 47 · see citing works
How long does covid-19 immunity last?
Baraniuk, C. (2021) · BMJ · doi:10.1136/bmj.n1605 · Cited by 45 · see citing works
Tomalka, J. A., Suthar, M. S., Deeks, S. G., & Sékaly, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01130-4 · Cited by 45 · see citing works
Self-citationYin, J., Chen, Y., Li, Y., Wang, C., & Zhang, X. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.10.005 · Cited by 45 · see citing works
- Authors
- Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., O’Dell, S., Schmidt, S. D., Widge, A. T., Edara, V.-V., Anderson, E. J., Lai, L., Floyd, K., Rouphael, N. G., Zarnitsyna, V., Roberts, P. C., Makhene, M., Buchanan, W., Luke, C. J., Beigel, J. H., Jackson, L. A., Neuzil, K. M., Bennett, H., Leav, B., Albert, J., & Kunwar, P.
- Affiliations
- National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD
- Emory University (US)
- Emmes (United States) (US)
- National Institutes of Health (US)
- NIAID, Bethesda, MD
- Kaiser Permanente Washington Health Research Institute (US)
- University of Maryland, Baltimore (US)
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Suthar, Mehul S.
- ORCID
- Doria-Rose, Nicole
- Suthar, Mehul S.
- Makowski, Mat
- O’Connell, Sarah
- McDermott, Adrian B.
- Ledgerwood, Julie E.
- Mascola, John R.
- Graham, Barney S.
- Lin, Bob C.
- Schmidt, Stephen D.
- Widge, Alicia T.
- Edara, Venkata-Viswanadh
- Anderson, Evan J.
- Lai, Lilin
- Floyd, Katharine
- Rouphael, Nadine G.
- Zarnitsyna, Veronika
- Roberts, Paul C.
- Beigel, John H.
- Jackson, Lisa A.
- Neuzil, Kathleen M.
- Bennett, Hamilton
- Leav, Brett
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-10
- Volume
- 384
- Issue
- 23
- Pages
- 2259-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8524784
- OpenAlex
- W3142193311
- Cited by
- 673
- References
- 6
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 40 · 2023: 104 · 2022: 287 · 2021: 199
- FWCI
- 49.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Covid-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine
- North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill
- North Carolina Coronavirus Relief Fund
- Coalition for Epidemic Preparedness Innovations
- Georgia Research Alliance
- National Institute of Allergy and Infectious Diseases (AI149644, HHSN272201500002C, P51 OD011132, UM1AI148373, UM1AI148576, UM1AI148684, UM1Al148684-01S1)
- National Center for Advancing Translational Sciences (UL1 TR002243)
- Dolly Parton COVID-19 Research Fund
- Emory Executive Vice President for Health Affairs Synergy Fund award
- Center for Childhood Infections and Vaccines
- Children’s Healthcare of Atlanta
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccination, antibody persistence, humoral immune response, Moderna vaccine, booster vaccination, SARS-CoV-2 antibodies
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adult, Aged, Antibodies, Viral, Half-Life, Humans, Middle Aged, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-06.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-06.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
